PriceTargets.com logo

Vivos Therapeutics - VVOS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.60
  • Forecasted Upside: 132.39%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.84 As of 11/15/2024 01:00 AM ET
▼ -0.28 (-8.97%)

This chart shows the closing price for VVOS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vivos Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VVOS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VVOS

Analyst Price Target is $6.60
▲ +132.39% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Vivos Therapeutics in the last 3 months. The average price target is $6.60, with a high forecast of $6.60 and a low forecast of $6.60. The average price target represents a 132.39% upside from the last price of $2.84.

This chart shows the closing price for VVOS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Vivos Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/20/2024Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$6.40 ➝ $6.60
1/17/2023Ascendiant Capital MarketsInitiated CoverageBuy
12/21/2022Roth CapitalReiterated RatingBuy
5/17/2022Craig HallumLower TargetNA$125.00
8/13/2021Roth CapitalLower TargetBuy$275.00 ➝ $250.00
5/18/2021Roth CapitalLower TargetBuy$300.00 ➝ $275.00
1/11/2021Craig HallumInitiated CoverageBuy$300.00
1/5/2021Roth CapitalInitiated CoverageBuy$300.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/21/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 5 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Vivos Therapeutics logo
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
Read More

Today's Range

Now: $2.84
Low: $2.76
High: $3.15

50 Day Range

MA: $2.79
Low: $2.29
High: $4.13

52 Week Range

Now: $2.84
Low: $1.91
High: $48.79

Volume

225,221 shs

Average Volume

169,199 shs

Market Capitalization

$13.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

7.71

Frequently Asked Questions

What sell-side analysts currently cover shares of Vivos Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Vivos Therapeutics in the last year: Ascendiant Capital Markets.
View the latest analyst ratings for VVOS.

What is the current price target for Vivos Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Vivos Therapeutics in the last year. Their average twelve-month price target is $6.60, suggesting a possible upside of 132.4%. Ascendiant Capital Markets has the highest price target set, predicting VVOS will reach $6.60 in the next twelve months. Ascendiant Capital Markets has the lowest price target set, forecasting a price of $6.60 for Vivos Therapeutics in the next year.
View the latest price targets for VVOS.

What is the current consensus analyst rating for Vivos Therapeutics?

Vivos Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VVOS will outperform the market and that investors should add to their positions of Vivos Therapeutics.
View the latest ratings for VVOS.

What other companies compete with Vivos Therapeutics?

Other companies that are similar to Vivos Therapeutics include InspireMD, Alpha Pro Tech, Nutriband, Milestone Scientific and Lucid Diagnostics. Learn More about companies similar to Vivos Therapeutics.

How do I contact Vivos Therapeutics' investor relations team?

The company's listed phone number is 866-908-4867 and its investor relations email address is [email protected]. The official website for Vivos Therapeutics is www.vivoslife.com. Learn More about contacing Vivos Therapeutics investor relations.